3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Refractory or Recurrent Solid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Myelomonocytic, Chronic
1
Hemangiosarcoma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Refractory or Recurrent Solid Tumor
×
spartalizumab
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled